Healthcare Equipment and Supplies
Company Overview of Ventana Medical Systems, Inc.
Ventana Medical Systems Inc. develops, manufactures, and markets instrument-reagent systems that automate slide staining. Its clinical systems are used in anatomical pathology labs in analyzing human tissue to assist in diagnosing and treating cancer and infectious diseases. Ventana’s drug-discovery systems are used by pharmaceutical and biotech companies to increase the discovery of new drug targets and to evaluate the safety of new compounds. It also markets consumable products, including reagents and other accessories, and serves hospital-based anatomical pathology labs, independent reference labs, government labs, medical research centers, and resellers serving these entities. Ventana Me...
1910 East Innovation Park Drive
Tucson, AZ 85755
Founded in 1985
Key Executives for Ventana Medical Systems, Inc.
Chief Executive Officer and Director
Founder, Chairman Emeritus, Chief Scientific Officer and Chief Medical Officer
Chief Financial Officer and Senior Vice President
Senior Vice President and General Counsel
Compensation as of Fiscal Year 2014.
Ventana Medical Systems, Inc. Key Developments
Ventana Medical Systems, Inc. Announces Collaboration to Develop Companion Diagnostics for ImmunoGen, Inc.'s Targeted Anticancer Agents
Oct 28 14
Ventana Medical Systems, Inc. announced it has entered into an agreement with ImmunoGen, Inc. to collaborate on the development of biomarker assays and a companion diagnostic immunohistochemistry (IHC) test for one or more of ImmunoGen's product candidates. Under this agreement, the companies have created an initial test for folate receptor alpha (FRa, also known as folate receptor 1, or FOL1) that is being used in early trials of IMGN853, ImmunoGen's FRa-targeting antibody-drug conjugate (ADC). Cancers that highly express FRa include epithelial ovarian cancer, endometrial cancer, and types of non-small cell lung cancers (NSCLC). The goal of the collaboration is to leverage Ventana's expertise in companion diagnostic development, from prototyping through regulatory approval and commercialization, to identify specific patient populations for ImmunoGen's bio-target directed therapies. This pharma collaboration is one of dozens currently underway where the Ventana Companion Diagnostics team is delivering patient stratifying diagnostic tools that help identify those individuals who are most likely to benefit from specific treatments. In addition to ImmunoGen, Ventana has announced collaborations with Bayer, Pfizer, Boehringer Ingelheim, Takeda's Millennium unit, Genmab, Incyte, MedImmune and more.
Ventana Medical Systems, Inc. Enters into Agreement with Quintiles, Inc. to Offer College of American Pathology-Standard Companion Diagnostic Testing Services in China
Aug 5 14
Ventana Medical Systems, Inc. announced a new agreement with Quintiles, Inc. to offer College of American Pathology (CAP)-standard companion diagnostic testing services in China for pharmaceutical and biotech companies conducting early phase clinical trials. Early phase clinical trial testing according to the rigorous CAP standards set by Ventana is available now.
Ventana Medical Systems, Inc. Enters into an Agreement with Merck KGaA to Develop Companion Diagnostic Test for Cancer Treatment
Jul 10 14
Ventana Medical Systems, Inc. announced it has entered into an agreement with Merck KGaA to collaborate with Merck KGaA's biopharmaceutical division on the development and commercialization of a companion diagnostic (CDx) for an undisclosed target using Ventana's proprietary diagnostic assays. In alignment with Merck KGaA's strategic approach in personalized medicine, the aim is to develop a patient stratifying diagnostic test that can be used in multiple cancer indications. Merck KGaA, which is actively investing in innovation in the CDx field through a number of partnerships, will leverage Ventana's global leadership position in cancer diagnostics and vast expertise in CDx to achieve new levels of diagnostic clarity for the investigated target. As part of the agreement, Ventana will develop and validate the CDx and ensure its readiness, availability, and adherence to FDA and other health authority standards for future clinical trials. This pharma partnership is one of several currently underway where the Ventana Companion Diagnostics team is delivering patient stratifying diagnostic tests that help identify those patients who are most likely to benefit from specific treatments. Companion diagnostics (CDx) are tests designed to confirm the presence of a specific biomarker to assist physicians in selecting effective therapies for their patients, based on the individual characteristics of each person. Incorporating a companion diagnostic strategy into a drug development program may expedite the drug approval process and help generate more effective treatments with improved safety profiles for patients.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|